American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6360)
  2. Solid Tumor Oncology Division (5501)
  3. Survivorship Research (1982)
  4. Genitourinary Oncology Service (1761)
  5. Surgery (1632)
  6. Epidemiology and Biostatistics (1476)
  7. GSK Faculty (1380)
  8. Population Sciences Research Program (1360)
  9. Gastrointestinal Oncology Service (1350)
  10. Hematologic Malignancies, Division of (1273)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2561)
  3. Editorial (73)
  4. Review (65)
  5. Guidelines (54)
  6. Correspondence (48)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6360)
  2. Solid Tumor Oncology Division (5501)
  3. Survivorship Research (1982)
  4. Genitourinary Oncology Service (1761)
  5. Surgery (1632)
  6. Epidemiology and Biostatistics (1476)

More Groups

People
  1. Robert Motzer (450)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (250)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8678)
  2. JCO Precision Oncology (166)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (4)

More Publications

Results (9142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts
    Meeting Abstract

    Witowski, J.; Choucair, K.; Elayoubi, J.; Chiru, E. D.; Chan, N.; Kang, Y. J.; Howard, F. M.; Ostrovnaya, I.; Schnabel, F. R.; Abdulsattar, W.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Pilot study of an enhanced telehealth program for patients with prostate cancer
    Meeting Abstract

    Bange, E. M.; Reiner, A. S.; Liebertz, C.; Chimonas, S.; Daly, R. M.; Malling, C.; Lei, S.; Campbell, R.; Stevanovic, K.; Holland, J. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)
    Meeting Abstract

    Razavi, P.; Cabel, L.; Teysir, J.; An, J. A. R.; Rivero-Hinojosa, S.; Satta, S.; Bristow, S. L.; Kalashnikova, E.; Rodriguez, A. A.; Liu, M. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cancer patients' messages about radiology/pathology reports: Insights for AI
    Meeting Abstract

    Chimonas, S.; Lipitz-Snyderman, A.; Kuperman, G.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Differences in insurance status among Asian Americans with cancer: A disaggregated analysis by ethnic subgroup
    Meeting Abstract

    Nguyen, L.; Nguyen, I.; Feng, E.; Feng, E. L. L.; Feliciano, E.; Dee, E. C.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Trends in female breast cancer among adolescent and young adults in Southeast Asia
    Meeting Abstract

    Chen, J.; Ho, F. D.; Wu, J. F.; Magsanoc-Alikpala, K.; Dee, E. C.; Feliciano, E. J. G.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study
    Meeting Abstract

    Nayak, L.; Grommes, C.; Kallam, A.; Peereboom, D. M.; Ambady, P.; Mendez, J. S.; Aregawi, D. G.; Sumrall, A. L.; Omuro, A. M. P.; Iwamoto, F.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors
    Meeting Abstract

    Schram, A. M.; Clay, T. D.; Prenen, H.; Park, J. J.; Lunger, L.; Hussain, J.; Maier, D.; Kitano, S.; Dumbrava, E. E.; Kim, H. D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • RYZ101 ((225)Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study
    Meeting Abstract

    Mayer, E. L.; Miller, K.; Jhaveri, K. L.; Yeh, R.; Sakach, E.; Prasad, V.; Ferreira, D. V.; Herszdorfer, P.; Gong, L.; Li, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors
    Meeting Abstract

    Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A.; Garofalo, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save